fda glp-1 warning letters september 2025 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines FDA takes aim at Hims

Over the two-year study period, patients receiving GLP-1based therapy experienced: Importantly, the study authors did not observe an increased risk for key diabetes-related complications, including diabetic ketoacidosis and hypoglycemia

R., Zhang, C

Here's what you can do: Talk to Your Doctor Before Starting GLP-1s: Discuss your medical history, including any prior gallbladder issues

[PubMed] [Google Scholar] 82

The aim is to make sure people use FDA-approved drug products, which are reviewed for their safety and how well they work as they move through the supply chain

The weight loss achieved with GLP-1 therapy appears central to hepatic benefits, as weight reduction of 710% consistently improves NAFLD across multiple intervention studies